Spectral Medical Inc (TSE:EDT) was downgraded by stock analysts at Cormark from a “buy” rating to a “reduce” rating in a note issued to investors on Monday.

Separately, GMP Securities reaffirmed a “speculative buy” rating on shares of Spectral Medical in a report on Wednesday, September 14th.

Spectral Medical (TSE:EDT) traded down 81.677% during midday trading on Monday, hitting $0.295. 12,272,747 shares of the stock traded hands. Spectral Medical has a 52-week low of $0.18 and a 52-week high of $2.07. The firm’s market cap is $60.99 million. The stock has a 50-day moving average of $1.30 and a 200 day moving average of $1.02.

About Spectral Medical

Spectral Medical Inc, formerly Spectral Diagnostics Inc, is a therapeutic development company. The Company is focused on the development and commercialization of a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) and the Toraymyxin (PMX) therapeutic. The Company also manufactures and sells certain reagents.

Receive News & Stock Ratings for Spectral Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Medical Inc and related stocks with our FREE daily email newsletter.